• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
RGD-4C

RGD-4C

Product ID R2510
Cas No.
Purity ≥95%
Product Unit SizeCostQuantityStock
1 mg $173.30 In stock
2 mg $325.50 Please Inquire
5 mg $551.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

RGD-4C is a cell-adhesive peptide that binds αvβ3 and αvβ5 integrins; these integrins are overexpressed in many cancers and growing vessels, so RGD-4C is often attached to viral treatments to better deliver or target the treatment to cancerous tissues. RGD-4C exhibits anticancer chemotherapeutic and anti-angiogenic benefits in models of various cancers, including non-small cell lung cancer (NSCLC), melanoma, and glioma.

Product Info

Purity

≥95%

Formula

C42H60N14O16S4

Formula Wt.

1145.29

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

Info Sheet

R2510 Info Sheet PDF

References

Allaume X, El-Andaloussi N, Leuchs B, et al. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J Virol. 2012 Apr;86(7):3452-65. PMID: 22258256.

Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. 2012 Apr 15;130(8):1937-47. PMID: 21630267.

Sarkioja M, Kanerva A, Salo J, et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer. 2006 Oct 1;107(7):1578-88. PMID: 16948124.

Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 2006 Apr;104(4):583-92. PMID: 16619663.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B8377

    5-tert-Butoxyquinazoline-2,4-diamine

    Diaminoquinazoline derivative.

    ≥98%
  • S8146

    Sulindac Sulfone

    NSAID; COX-1/2 and PDE inhibitor.

    ≥98%
  • T1855

    Tentoxin

    Cyclic peptide mycotoxin produced by Alternaria...

    ≥98%, HPLC
  • C0262

    L-Carnitine

    Endogenous quaternary ammonium, required for fa...

    ≥98%
  • S8110

    Sucralfate

    Antacid; pepsin inhibitor. Assay (Polysaccharid...

    Assay (Polysaccharide sulfate) 30-38%
  • A724092

    Asciminib Hydrochloride

    Allosteric inhibitor

    ≥98%
  • R0348

    Ramelteon

    Melatonin analog; MT1/2 agonist.

    ≥99%
  • G346851

    Givinostat Hydrochloride

    Non-selective HDAC inhibitor.

    ≥98%
  • H9718

    2-Hydroxyflutamide

    Non-steroid; AR antagonist.

    ≥98%
  • B030966

    BAY 11-7082

    inhibits inflammatory signaling

    ≥98%
  • N1868

    Neratinib

    EGFR inhibitor.

    ≥98%
  • H1893

    Hexarelin

    Synthetic ghrelin analog; ghrelin agonist.

    ≥95%
  • D604080

    DpC

    Anti-metastatic

    ≥99%
  • I7659

    1-Isothiocyanato-8-(methylsulfonyl)-octane

    ITC, erysolin analog.

    ≥98%
  • T2833

    1-Thio-β-D-glucose Tetraacetate

    Imaging agent; Maillard reaction inhibitor.

    ≥98%
  • S824766

    Sutezolid

    Bactericidal.

    ≥98%
  • I530280

    INH1

    Hec1/Nek2 mitotic pathway inhibitor

    ≥98%
  • S8145

    Sulindac

    NSAID; COX-1/2 and PDE inhibitor.

    ≥99%
  • E846184

    Everolimus EP Impurity B

    Everolimus impurity

    ≥96% (mix of E/Z)
  • C9882

    Cytochalasin E

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only